Cargando…
Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease
SSc is a rare CTD that affects multiple organ systems, resulting in substantial morbidity and mortality. Evidence of interstitial lung disease (ILD) is seen in ∼80% of patients with SSc. Currently there is no approved disease-modifying treatment for ILD and few effective treatment options are availa...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6434373/ https://www.ncbi.nlm.nih.gov/pubmed/29893938 http://dx.doi.org/10.1093/rheumatology/key151 |